Glioblastoma, the most common and aggressive type of brain cancer claimed the life of Sen. Edward Kennedy and 17,000 others every year. Conventional treatments have never offered much help to patients with brain cancer.

We need alternative treatments, using the immune systems. Just like the vaccines we give for measles, mumps and the flu, the idea is to prevent cancer from coming back. Dr. Andrew Parsa, a University of California at San Fransisco (UCSF) neurological surgeon who is leading the study of the vaccine, called Oncophage, with $150,000 in funding from the National Brain Tumor Society and other patient groups and another $150,000 from the federal government. Dr. Parsa is testing that theory with a ground-breaking clinical trial at UCSF Medical Center. Working with a biotech company, his team used a piece of Wheatley's tumor, to create a vaccine engineered to target specific cancer. A woman Joyce Wheatley became the first in the country to try a new vaccine to stop a brain tumor from reoccurring. The idea is to combine the tumor vaccine early, while the cancer is being weakened by chemotherapy and radiation. The hope is patients will then be able to manage the disease using their own immune system.

Traditional chemotherapeutic drugs don't work well in combating this type of cancer. Part of the problem is the body's blood-brain barrier, which is designed to shield the organ from chemicals - but also blocks lifesaving therapies from reaching it. Tumor cells also become quickly resistant to medicines. Vaccines, also called immunotherapies, take a different approach. Using a multistep approach, they are created from a patient's own tumor. The vaccine actually provokes a tumor-specific immune response that is patient specific. T-cells, the killer compound of the immune system, track down the cancer and try to kill it.

The approach seems counterintuitive - if the body's natural immune response could combat the cancer, the tumor should have perished and never needed treatment. A more vigorous defense is needed. If it works, it will reinvigorate a strategy for treating cancer that has long held conceptual promise but has proved difficult to deliver.

Many experimental vaccines have stumbled in clinical trials and none is yet approved in the United States. One of the greatest disappointments was in 2005, when final testing of the anti-melanoma vaccine Canvaxin showed that people getting the drug did not live longer than those getting the placebo. This year, a drug named Provenge, an immunotherapy for prostate cancer, has been shown to lengthen life for four months but has not yet earned approval by the U.S. Federal Drug Administration.

Scientists say that one challenge is that most drugs in development are first evaluated in patients with fairly advanced cancer - but many of these patients are so sick that they're immune-suppressed. Cancer vaccines may work better when the tumor is smaller. Scientists also say that ‘one should have to have the right type of vaccine, the right type of cancer, the right type of patient and the right type of environment to cure’.

Any chemicals that have a useful function in the production, processing, or preservation of foods or drinks may nevertheless be toxic, and possibly mutagenic or carcinogenic. For this reason, food additives and contaminants, such as traces of chemicals used in industrial agricultural production, are subject to international and national surveillance and regulations.

They are a cause for concern and vigilance because some, and in particular agricultural chemicals, are known to be toxic in experimental settings, though at levels well above those found in foods and drinks.

There is little epidemiological evidence on the possible effects of contaminants and additives as present in foods and drinks.

Because contaminants and additives are subject to international and national regulation, there is a vast amount of toxicological information from experiments on laboratory animals and other settings. Failing any other method, it seems reasonable to observe the effects of food additives and contaminants on laboratory animals at levels greatly in excess of any likely to be present in foods and drinks; and based on several assumptions and judgements, to set limits for safety in use. When such limits are used as regulatory limits, they are also subject to surveillance and special investigation when any chemical present in foods and drinks seems to be a cause for special concern.

This are remains controversial. Theoretically, it would be ideal if food supplies contained no trace of any toxic substance, including those that are or may be mutagenic or carcinogenic. However, some foods in nature contain carcinogens and the issue is not confined to methods of industrial food processing.

Helicobacter Pylori (H. pylori) is a bacterium that lives in the human stomach. Infection does not usually produce symptoms, and spreads through saliva and fecal material. Prevalence increases with age, but differs dramatically among populations. In the USA, prevalence is less than 20 per cent at 20 years old and about 50 per cent at 50 years, which may be typical of high-income countries, while in Korea, it is 50 per cent at 5 years and 90 per cent at 20 years, and in Japan it reaches 85 per cent by middle age.

H. pylori colonises the gastric mucosa and elicits both inflammatory and immune lifelong responses, including the release of various bacterial and host-dependent cytotoxic substances. H. pylori infection greatly reduces the bioavailability of vitamin C. this may play a role in the development of stomach cancer in the presence of dietary and other factors that are a cause of this cancer. In studies of precancerous lesions or gastric atrophy, eradication of H. pylori promoted regression of these cancer precursors.

Some people develop stomach cancer without apparent infection with H. pylori. Reported percentages of non-cardia cancers that test positive for H. pylori range from approximately 60 to 95 per cent, averaging around 86 per cent, but those with distal stomach cancer who test negative for H. pylori may have undergone a loss of infection associated with the atrophic gastritis, and consequently a decline in antibody titre. It can be regarded as a necessary cause for those stomach cancers arising in the distal region of the stomach.

The longer the time of infection, and the greater the impact on the gastric mucosa, the more likely it is that stomach cancer will develop and take a severe form. The exact site of the cancer is most likely to be where the mucosa is most affected. Those who develop extensive gastritis and gastric atrophy are at increased risk of developing cancer.

It was famously linked with stomach ulcers by two Australian researchers (Barry Marshall and J. Robin Warren)-one of whom deliberately infected himself to prove the theory- who were awarded the Nobel Prize for their discovery in 2005. The World Health Organization also classes the H. pylori as a leading cause of stomach cancer. Preventing stomach cancer by eradicating H. pylori in high-risk regions should be a priority.

Hepatitis B and hepatitis C viruses are causes of liver cancer. The former appears to act directly by damaging cells and their DNA. The latter shows an indirect effect, mediated by cirrhosis. For both, there is potential for nutrition status to have an effect at several stages: susceptibility to and duration of infection, liver damage, DNA damage, and cancer progression (Refer Figure 2 in Nutrition and Cancer).

Around 7-8 per cent of the world’s population is estimated to be infected with hepatitis B virus. It is mostly spread by blood and sexual transmission. In endemic areas, the carrier rate may be 10-20 per cent. It is often acquired at birth or in childhood, and is endemic in areas of Africa and Asia. Chronic hepatitis B virus carriers have a 100-fold greater chance of developing liver cancer than non-carriers. Those infected in adulthood have a lower risk of this cancer than those infected in childhood because there is less time for virus to cause inflammation. Vaccination against hepatitis B virus has been shown to reduce the prevalence of liver cancer by 60 per cent.

Liver cancer in hepatitis B virus carriers is not necessarily connected with cirrhosis: up to 40 per cent of associated liver cancer cases are non-cirrhotic. Hepatitis B virus carries its genetic code as DNA rather than RNA. Viral DNA can insert itself into liver cells and alter their DNA.

Around 3 per cent of the world’s population is estimated to be infected with hepatitis C virus. It is more prevalent in high income countries. Approximately 80 per cent of these infections become chronic, of which 15-20 per cent develops into cirrhosis. Of those, 1-4 per cent develops into liver cancer each year. Interruption of the sequence of chronic hepatitis developing into cirrhosis prevents liver cancer. Also, there is an interaction between hepatitis C virus infection, liver cancer risk, and consumption of alcoholic drinks. There is no vaccine against hepatitis C. It is mostly spread by blood.

The majority of cancers are not inherited. Cancer is, however, a disease of altered gene expression that originates in changes to DNA, the carrier of genetic information. For a cell to be transformed from normal to cancerous, it has to acquire different phenotype characteristics that result from alterations to the genotype. Most cancers develop to the stage of being clinically identifiable only years or decades after the initial DNA damage. 

Cancer development, or carcinogenesis, requires a series of cellular changes. No single gene causes cancer. It is a multistep process caused by accumulated errors in the genes that control cellular processes. One genetic mutation may allow a single trait (such as increased survival) to be acquired by a lineage of cells and descendants of these cells may then acquire additional genetic mutations. However, cancer only develops when several genes are altered that confer growth and survival advantages over neighboring normal cells. 

The capacity of a cell to achieve effective cancer prevention or repair is dependent on the extracellular microenvironment, including the availability of energy and the presence of appropriate macro- and micronutrients. Tumors are not simply masses of cancer cells. Rather, they are heterogenous collections of cancer cells with many other cell types-so called stromal cells; cancer cells communicate with stromal cells within the tumor. The tumor microenvironment comprises many cell types including infiltrating immune cells such as lymphocytes and macrophages, endothelial cells, nerve cells, and fibroblasts. All these cell types can produce growth factors, inflammatory mediators, and cytokines, which can support malignant transformation and tumor growth, and attenuate host responses. In addition, factors produced by the cancer cells themselves modulate the activity and behavior of the tumor stroma.

Initiation is the exposure of a cell tissue to an agent that results in the first genetic mutation. This can be an inherited mutation or an exogenous or endogenous (produced through oxidative metabolism) factor. Even without external oxidative stress, hundreds of sites within DNA are damages each day but are normally repaired or eliminated. 

Exposure to the carcinogen initiates DNA damage, usually via the formation of DNA adducts. If left uncorrected, these adducts can be transferred to daughter cells during division and confer the potential for neoplastic (new and abnormal) growth. 

Initiation alone is insufficient for cancer to develop. An initiated cell must go through a process of clonal expansion during promotion to become neoplastic; the larger the number of initiated cells, the greater the risk of progressing to cancer. Promotion involves exposure of the initiated cell to a promoting agent. This may allow alterations in the rate of proliferation or additional DNA damage to occur, leading to further mutations within the same cell, which alter gene expression and cellular proliferation. Finally, these initiated and promoted cells grow and expand to form a tumor mass. DNA damage continues at this stage and cancer cells often contain multiple copies of chromosomes. This clear, sequential process is typical of experimentally induced cancers but may be less clear in sporadic cancers in humans. 

Figure 1. The six hallmarks of cancer. Cancer cells have different charecteristics from normal cells. The six hallmarks shown here are the phenotypic changes that need to be accumulated over time as a result of genetic changes (mutations and epigenetic factors) in order for a cell to become cancerous. 

At the end of multistage process of carcinogenesis, the cell will bear some or all of the hallmarks of cancer (Figure 1). Several genes can contribute to each hallmark and one gene (for example p53) can contribute to several of the hallmarks. These hallmarks or traits are shared by most, if not all, cancer cells. The six hallmarks of cancer cells are self sufficiency in growth signals; insensitivity to antigrowth signals; limitless replicative potential; evasion of apoptosis; sustained angiogenesis; and tissue evasion and metastasis. Food, nutrition and physical activity related factors influence cellular processes and lead to cells accumulating these traits (Figure 2). The figure 2 describes the strength of evidence for suggesting relationships between numerous factors that enhance or reduce cancer risks.

Figure 2. The influence of food, nutrition, obesity and physical activity on the processes of cancer.

Reference: World Cancer Research Fund International and the American Institute for Cancer Research released reports.